Objective: To investigate the protective effects of against isoniazid (INH) and rifampicin (RFP)-induced hepatic and pancreatic damage.
Methods: Eighty adult rats were randomly divided into eight groups; Control; INH; RFP; INH+RFP; INH+CAPE; RFP+CAPE; INH+RFP+CAPE; CAPE. Both INH and RFP was orally administered for 30 days at a dose of 50mg/kg/day. CAPE was intraperitoneally injected for 30 days (10 μmol/kg). Blood samples, hepatic and pancreatic tissues were obtained on day 30.
Results: Total oxidant status levels were significantly higher in INH and/or RFP-treated groups than those of control and CAPE groups, while total antioxidant status and paraoxonase-1levels were significantly reduced in INH-RFP groups compared with the group receiving CAPE.
Histopathological deterioration was observed in RFP and INH groups in pancreatic and hepatic tissue. However, significant amelioration was observed in CAPE-treated groups.
Conclusion: Our findings suggest that CAPE may be a promising agent to prevent the side effects of INH and RFP treatment on hepatic and pancreatic tissues.
Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.